Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received an average rating of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $25.20.
A number of research firms recently issued reports on ATXS. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Friday, September 27th. Wedbush reissued an "outperform" rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer raised their target price on Astria Therapeutics from $25.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. Finally, TD Cowen initiated coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a "buy" rating and a $35.00 price objective on the stock.
Check Out Our Latest Analysis on Astria Therapeutics
Shares of ATXS stock opened at $11.87 on Friday. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The firm has a market capitalization of $651.82 million, a PE ratio of -5.12 and a beta of 0.71. The stock's 50-day simple moving average is $11.30 and its 200-day simple moving average is $10.76.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Sell-side analysts forecast that Astria Therapeutics will post -1.66 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of ATXS. SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $155,000. Cubist Systematic Strategies LLC acquired a new position in Astria Therapeutics during the second quarter worth $2,561,000. Nantahala Capital Management LLC acquired a new position in Astria Therapeutics during the second quarter worth $6,142,000. Susquehanna Fundamental Investments LLC purchased a new position in Astria Therapeutics during the second quarter valued at $400,000. Finally, Millennium Management LLC grew its position in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock valued at $16,763,000 after purchasing an additional 218,518 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.